Malone, Amanda Michelle — Insider Profile

Insider Profile

Malone, Amanda Michelle

$EPRX

Companies Filed At

Open-Market Buys (2yr)

—

Buy Value (2yr, open-market)

Dec 15, 2025

Most Recent Trade

Credibility
Score

33%

Hit Rate

-9.1%

Avg 90d Return

-6.3%

Median 90d Return

Evaluated Trades

+18.4%

Best Trade

-39.3%

Worst Trade

Hit rate and returns are based on 3 open-market buys with evaluable 90-day outcomes. Score reflects historical conviction, not a guarantee of future performance. Limited signal — either below-average timing or insufficient trade history.

Date	Company	Role	Nature	Dir.	Shares	Price	Value	Score
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	26,000	$8.63	$224K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	59,750	$8.63	$516K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	26,000	$8.63	$224K	60
Dec 15, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	59,750	$8.63	$516K	60
Nov 02, 2025	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	3,750	$8.00	$30K	60
Mar 31, 2025	$EPRX Eupraxia Pharmaceuticals	—	Expiry	Sell	12,500	$8.00	$100K	60
Mar 25, 2025	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	130,000	$5.14	$668K	60
May 13, 2024	$EPRX Eupraxia Pharmaceuticals	—	Comp. Grant	Buy	175,000	$3.96	$693K	60
Aug 18, 2023	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Sell	7,143	$7.00	$50K	60
Mar 09, 2021	$EPRX Eupraxia Pharmaceuticals	—	Open Market	Buy	75,000	$8.00	$600K	60

Muted rows are plan purchases, compensation grants, or DRIP — not open-market. Signal scores reflect the company's current score, not the score at time of trade.